Finland· FI-REL-REL62236
Rybelsus
A semaglutide product containing semaglutide, registered in Finland by Novo Nordisk A/S. The same ATC class is registered in 14 of our 19 countries.
Checked against Fimea (Finland) on
Informational only — not a medical device.
Where it is registered
Semaglutide is registered in 14 of 19 countries.
Countries holding a registration under ATC A10BJ06 (semaglutide), each read from that country’s own register.
- This record: Finland, from Fimea (Finland)
- 9 of them publish a price we can compare per daily dose
Semaglutide · ATC A10BJ06
14 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Icelandprice
- Ireland
- Italyprice
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
- United Kingdom
- United Statesprice
Price per daily dose
What a daily dose of semaglutide costs, country by country.
Normalised to the WHO defined daily dose (10.5 mg), the median price runs from $11.85 in Italy to $430.99 in Switzerland — a ×36 gap.
- 2 markets with a comparable price for this class
- Public list prices, converted to USD at the rate date shown
Semaglutide · price per daily dose (10.5 mg)
USD · FX 28 Sept 2026
- CH Switzerland$430.99
- IT Italy$11.85
The record
At a glance
Fimea (Finland)- Active substance
- Semaglutide
- Manufacturer
- Novo Nordisk A/S
- Country
- Finland (FI)
- ATC code
- A10BJ06
- ATC class
- Semaglutide
- Defined daily dose
- 10.5 mg, O
- Reimbursed
- Not published by this register
- Source register
- Fimea (Finland)
- Last checked
- September 27, 2026
Packs & prices · 0
No packs listed by the register for this record.
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
301 interactions on record for semaglutide.
Graded by severity as the source publishes them — 3 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Semaglutide · interactions on record
301 records
- 3 severe
- 258 moderate
- 40 minor
Most severe, free to view
- GatifloxacinJ01MA16severe
- SucralfateA02BX02moderate
- ThiethylperazinA04AB03moderate
- TriflupromazinA04AD06moderate
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Semaglutide in 16 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- CzechiaRYBELSUSNovo Nordisk A/S, Bagsvaerd
- United StatesOZEMPICNovo Nordisk Pharmaceutical Industries, LP
- SwitzerlandRybelsus N 4 mg, TablettenNovo Nordisk Pharma AG
- SpainRYBELSUS 4 MG COMPRIMIDOSNovo Nordisk A/S
- IrelandRybelsus 4 mg tabletsNovo Nordisk A/S
- NetherlandsRybelsus 4 mg tablettenNovo Nordisk A.S.
- PolandRybelsusNovo Nordisk A/S
- SwedenRybelsus 4 mg TablettNovo Nordisk A/S
Authorised across Europe · EMA
The same active substance is authorised in 2 EEA countries. Names it is sold under:
- Iceland · Kayshild, Ozempic
- Norway · Kayshild, Ozempic
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Fimea (Finland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/cdc1079b-bdbf-4893-bf84-804d9642f1af GET /v1/drugs/cdc1079b-bdbf-4893-bf84-804d9642f1af?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"ddd": "10.5",
"form": "tabletti",
"route": "Suun kautta",
"ddd_unit": "mg",
"strength": "4 mg",
"atc_label": "semaglutidi",
"ma_number": null,
"auth_status": "Myyntilupa myönnetty",
"eu_ma_number": "EU/1/20/1430/021-025",
"fimea_rel_id": "REL62236",
"authorised_at": "2024-08-01"
}See everything about semaglutide.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.